NCT03152877View on ClinicalTrials.gov

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Partum Pain Management Following Obstetrical Laceration

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Pain, Obstetric
Interventions
DRUG

Bupivacaine Liposome Injectable Product

20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.

DRUG

0.25% plain bupivacaine

20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.

Trial Locations (1)

20814

Walter Reed National Military Medical Center, Bethesda

All Listed Sponsors
lead

Walter Reed National Military Medical Center

FED

NCT03152877 - Efficacy of Extended-Release Liposomal Bupivacaine for Post-Partum Pain Management Following Obstetrical Laceration | Biotech Hunter | Biotech Hunter